Cristina Martucci

Dr. Cristina Martucci

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Frontiers in Pediatrics
Verified
Journal Article
Open access
CMCristina Martucci
Cristina Martucci
ACAlessandro Crocoli
Alessandro Crocoli
MPMaria Debora De Pasquale
Maria Debora De Pasquale
CSClaudio Spinelli
Claudio Spinelli
SSSilvia Strambi
Silvia Strambi
AIAlessandro Inserra
Alessandro Inserra
Background: Thyroid gland malignancies are rare in pediatric patients (0.7% of tumors); only 1.8% are observed in patients aged 0.999). Secondary tumors showed a higher incidence of disease relapse (OR 1.556, 95% CI.4579-5.57, p = 0.4525) and surgical complications (OR 2.042, 95% CI 0.7917–5.221, p = 0.1614), including hypoparathyroidism and recurrent laryngeal nerve injury. The overall survival (OS) was 99% at 1 year and 97% after 10 years. No EFS differences were evident between the primary and secondary tumors (chi-square 0.7307, p = 0.39026).Conclusions: This multicenter study demonstrated excellent survival in pediatric thyroid malignancies. Secondary tumors exhibited greater disease relapse (15.8 vs. 10.5%) and a higher incidence of surgical complications (36.8 vs. 22.2%).

4 June 2021 in The Journal of Vascular Access
Verified
Journal Article
Closed access
PDF file
ACAlessandro Crocoli
Alessandro Crocoli
CMCristina Martucci
Cristina Martucci
LSLuca Sidro
Luca Sidro
DDDaniela Delle Donne
Daniela Delle Donne
GMGiuseppe Menna
Giuseppe Menna
AIAlessandro Inserra
Alessandro Inserra
Background: Proper securement of central venous catheters plays an important role in onco-hematological pediatric patients. A new subcutaneously anchored securement device has been recently introduced in the clinical practice, and it has been extensively used in children. Method: In our study, we have retrospectively investigated the safety and the effectiveness of such device, reviewing the experience of three Italian pediatric oncological units. We have considered only tunneled catheters (cuffed or non-cuffed) inserted in children with malignancy; all types of tunneled central catheters were included in the analysis (both centrally and peripherally inserted) as long as they were secured with a subcutaneously anchored device. We investigated the incidence of dislodgment and of other catheter-related complications, with special attention to local adverse effects potentially related to the securement device. Results: We collected data from 311 tunneled catheters of different caliber: 80.4% were centrally inserted central catheters (CICC), 15.4% were peripherally inserted (PICC), and 4.2% were femorally inserted. Approximately half of the catheters (51%) were non-cuffed. Incidence of dislodgment was very low (2.6%) and the incidence of local pain or inflammation potentially related to the securement device was minimal (1.9%). Catheter related bacteremias were below 1 episode/1000 catheter days. No symptomatic catheter related thrombosis was reported. There was no significant difference in complications comparing cuffed versus non-cuffed catheters, or CICCs versus PICCs, or hematologic tumors versus solid tumors. Conclusion: In our retrospective analysis of a vast population of oncological pediatric patients with tunneled central catheters, the subcutaneously anchored securement device was tolerated very well, and it was highly effective in preventing dislodgment, both in cuffed and non-cuffed catheters.

5 January 2022 in Children
Verified
Journal Article
Open access
PDF file
ACAlessandro Crocoli
Alessandro Crocoli
CMCristina Martucci
Cristina Martucci
GPGiorgio Persano
Giorgio Persano
MPMaria Debora De Pasquale
Maria Debora De Pasquale
ASAnnalisa Serra
Annalisa Serra
AIAlessandro Inserra
Alessandro Inserra
Management and successful use of vascular access are critical issues in pediatric patients affected by malignancies. Prolonged course of disease, complex and various treatment protocols require long-lasting vascular access providing adequate tools to administrate those therapies and to collect routine blood sampling without painful and repeated venipuncture. For these reasons, central venous catheters are currently an important component in pediatric onco-hematological care, with a direct influence on outcome. Indeed, there are peculiar issues (techniques of insertion, management, complications etc.) which must be well-known in order to improve the outcome and the quality of life of children with cancer.

10 June 2024 in The Journal of Vascular Access
Verified
Journal Article
Closed access
MPMauro Pittiruti
Mauro Pittiruti
ACAlessandro Crocoli
Alessandro Crocoli
CZClelia Zanaboni
Clelia Zanaboni
MAMaria Giuseppina Annetta
Maria Giuseppina Annetta
MBMichela Bevilacqua
Michela Bevilacqua
GPGilda Pepe
Gilda Pepe
In pediatric patients, the choice of the venous access device currently relies upon the operator’s experience and preference and on the local availability of specific resources and technologies. Though, considering the limited options for venous access in children if compared to adults, such clinical choice has a great critical relevance and should preferably be based on the best available evidence. Though some algorithms have been published over the last 5 years, none of them seems fully satisfactory and useful in clinical practice. Thus, the GAVePed—which is the pediatric interest group of the most important Italian group on venous access, GAVeCeLT—has developed a national consensus about the choice of the venous access device in children. After a systematic review of the available evidence, the panel of the consensus (which included Italian experts with documented competence in this area) has provided structured recommendations answering 10 key questions regarding the choice of venous access both in emergency and in elective situations, both in the hospitalized and in the non-hospitalized child. Only statements reaching a complete agreement were included in the final recommendations. All recommendations were also structured as a simple visual algorithm, so as to be easily translated into clinical practice.

4 October 2022 in Frontiers in Pediatrics
Verified
Journal Article
Open access
CMCristina Martucci
Cristina Martucci
ACAlessandro Crocoli
Alessandro Crocoli
GPGiorgio Persano
Giorgio Persano
MBMarco Bonito
Marco Bonito
ASAlessandra Stracuzzi
Alessandra Stracuzzi
AIAlessandro Inserra
Alessandro Inserra
Uterine leiomyomas are rare in the pediatric population with less than 20 cases in adolescences reported in the literature. Furthermore, these masses represent a common presentation of gynecologic tumors with increasing age. We report a case of a 14-year-old female who presented with abdominal pain and increasing abdominal girth. Workup with ultrasound, CT and MRI demonstrated a large pelvic mass. Complete resection by median laparotomy was performed. The mass weighed 5,596 g and was 29.5 cm × 27 cm × 19 cm; the pathological examination confirmed the hypothesis of leiomyoma. The patient remained asymptomatic at 3 months follow up.

4 June 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
FBFederico Beati
Federico Beati
GPGiorgio Persano
Giorgio Persano
MPMaria Debora De Pasquale
Maria Debora De Pasquale
CMCristina Martucci
Cristina Martucci
SMSilvia Madafferi
Silvia Madafferi
AIAlessandro Inserra
Alessandro Inserra
Introduction: Patients affected by metastatic germ cell tumors may occasionally experience enlargement of masses with concurrent normalization of tumor markers during or after chemotherapy. This phenomenon is described as growing teratoma syndrome (GTS). The aim of the pre sent study is to assess the prevalence of GTS in the pediatric population and its implications in terms of surgical outcome. Patients and methods: The clinical notes of patients diagnosed with stage III and IV malignant germ cell tumors from January 2010 until December 2020 at our Institution were retrospectively reviewed. The prevalence of GTS, treatment strategies, survival, and outcome were analyzed. Results: Thirty‐three patients with high‐stage malignant germ cell tumors were diagnosed in our institution in the analyzed period. Nine patients (28%) had radiologic evidence of enlargement of persistent masses with normal markers after chemotherapy; these patients were classified as GTS patients. All nine patients underwent resection of metastatic lymph nodes, and six had surgery on visceral metastases. In six patients, radical excision of all metastatic sites was achieved; five patients are alive and in complete remission, while one died because of peri‐operative complications. Out of the three patients who could not achieve radical excision of the metastases, two died of progressive disease, and one is alive with progressive disease. Conclusions: Patients affected by GTS have a risk of progression of chemotherapy‐resistant disease and death. Radical surgical excision is essential to achieve disease control and long‐term survival.